Bio-Rad Laboratories Statistics
Total Valuation
BIO has a market cap or net worth of $9.06 billion. The enterprise value is $8.88 billion.
Important Dates
The last earnings date was Wednesday, October 30, 2024, after market close.
Earnings Date | Oct 30, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BIO has 28.00 million shares outstanding. The number of shares has decreased by -3.47% in one year.
Current Share Class | 22.92M |
Shares Outstanding | 28.00M |
Shares Change (YoY) | -3.47% |
Shares Change (QoQ) | -1.44% |
Owned by Insiders (%) | 16.03% |
Owned by Institutions (%) | 70.48% |
Float | 19.43M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 28.09 |
PS Ratio | 3.56 |
Forward PS | 3.30 |
PB Ratio | 1.21 |
P/TBV Ratio | 1.34 |
P/FCF Ratio | 36.68 |
P/OCF Ratio | 22.00 |
PEG Ratio | 2.34 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 18.38, with an EV/FCF ratio of 35.96.
EV / Earnings | n/a |
EV / Sales | 3.44 |
EV / EBITDA | 18.38 |
EV / EBIT | 26.61 |
EV / FCF | 35.96 |
Financial Position
The company has a current ratio of 6.14, with a Debt / Equity ratio of 0.19.
Current Ratio | 6.14 |
Quick Ratio | 4.21 |
Debt / Equity | 0.19 |
Debt / EBITDA | 2.52 |
Debt / FCF | 5.62 |
Interest Coverage | 6.80 |
Financial Efficiency
Return on equity (ROE) is -9.79% and return on invested capital (ROIC) is 2.23%.
Return on Equity (ROE) | -9.79% |
Return on Assets (ROA) | 1.85% |
Return on Capital (ROIC) | 2.23% |
Revenue Per Employee | $321,321 |
Profits Per Employee | -$96,973 |
Employee Count | 8,030 |
Asset Turnover | 0.23 |
Inventory Turnover | 1.48 |
Taxes
Income Tax | -226.50M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.13% in the last 52 weeks. The beta is 0.94, so BIO's price volatility has been similar to the market average.
Beta (5Y) | 0.94 |
52-Week Price Change | +8.13% |
50-Day Moving Average | 340.26 |
200-Day Moving Average | 317.25 |
Relative Strength Index (RSI) | 39.03 |
Average Volume (20 Days) | 218,501 |
Short Selling Information
The latest short interest is 651,703, so 2.33% of the outstanding shares have been sold short.
Short Interest | 651,703 |
Short Previous Month | 851,290 |
Short % of Shares Out | 2.33% |
Short % of Float | 3.35% |
Short Ratio (days to cover) | 3.36 |
Income Statement
In the last 12 months, BIO had revenue of $2.58 billion and -$778.69 million in losses. Loss per share was -$27.41.
Revenue | 2.58B |
Gross Profit | 1.41B |
Operating Income | 333.89M |
Pretax Income | -1.73B |
Net Income | -778.69M |
EBITDA | 483.49M |
EBIT | 333.89M |
Loss Per Share | -$27.41 |
Full Income Statement Balance Sheet
The company has $1.62 billion in cash and $1.39 billion in debt, giving a net cash position of $234.38 million or $8.37 per share.
Cash & Cash Equivalents | 1.62B |
Total Debt | 1.39B |
Net Cash | 234.38M |
Net Cash Per Share | $8.37 |
Equity (Book Value) | 7.49B |
Book Value Per Share | 267.46 |
Working Capital | 2.56B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $412.00 million and capital expenditures -$164.93 million, giving a free cash flow of $247.07 million.
Operating Cash Flow | 412.00M |
Capital Expenditures | -164.93M |
Free Cash Flow | 247.07M |
FCF Per Share | $8.82 |
Full Cash Flow Statement Margins
Gross margin is 54.54%, with operating and profit margins of 12.94% and -30.18%.
Gross Margin | 54.54% |
Operating Margin | 12.94% |
Pretax Margin | -38.96% |
Profit Margin | -30.18% |
EBITDA Margin | 18.74% |
EBIT Margin | 12.94% |
FCF Margin | 6.93% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 3.47% |
Shareholder Yield | 3.47% |
Earnings Yield | -8.59% |
FCF Yield | 2.73% |
Dividend Details Analyst Forecast
The average price target for BIO is $411.00, which is 26.97% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $411.00 |
Price Target Difference | 26.97% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | 3.35% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
Last Split Date | Mar 8, 2002 |
Split Type | Forward |
Split Ratio | 2:1 |
Scores
BIO has an Altman Z-Score of 3.43 and a Piotroski F-Score of 6.
Altman Z-Score | 3.43 |
Piotroski F-Score | 6 |